Evolution of plasma specific fibrin degradation products during thrombolytic therapy in patients with thrombo-embolism
- 15 May 1988
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 50 (4) , 583-589
- https://doi.org/10.1016/0049-3848(88)90206-x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.Circulation, 1987
- Specific Determination and Identification of Cross-Linked Fibrin Degradation Products in Patients Under Thrombolytic Therapy for Myocardial InfarctionSeminars in Thrombosis and Hemostasis, 1987
- Controversies of Different Regimens of Thrombolytic Therapy in Acute Pulmonary EmbolismSeminars in Thrombosis and Hemostasis, 1987
- Massive Pulmonary Embolism: Short-Term Effects of Thrombolytic TreatmentAngiology, 1986
- Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosisThe American Journal of Medicine, 1984
- Improved method for IgG purification from various animal species by ion exchange chromatographyJournal of Immunological Methods, 1984
- Thrombolytic TherapyNew England Journal of Medicine, 1982
- Production of monoclonal antibodies: Strategy and tacticsJournal of Immunological Methods, 1980
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975
- Comparison of Streptokinase and Heparin in Treatment of Isolated Acute Massive Pulmonary EmbolismBMJ, 1971